Literature DB >> 26114752

The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories.

Kyle C Strickland1, Brooke E Howitt1, Ellen Marqusee2, Erik K Alexander2, Edmund S Cibas1, Jeffrey F Krane1, Justine A Barletta1.   

Abstract

BACKGROUND: Increased recognition of the indolent nature of noninvasive follicular variant of papillary thyroid carcinoma (NFVPTC) along with greater insight into the molecular alterations of these tumors has prompted endocrine pathologists to question whether these tumors warrant a diagnosis of carcinoma. However, a change in terminology would affect the rates of malignancy of fine-needle aspiration (FNA) diagnostic categories. Therefore, the aim of this study was to determine the percentage decrease in associated risk of malignancy for each FNA diagnostic category if NFVPTCs were no longer termed carcinomas.
METHODS: We evaluated a cohort of 655 FNAs with subsequent resection specimens over a 22-month time period. The diagnoses of the preceding FNAs were recorded according to the Bethesda System for Reporting Thyroid Cytopathology. For cases with more than one preceding FNA, the FNA diagnosis associated with the highest risk of malignancy was identified. Slides for all resection specimens with a diagnosis of FVPTC were reviewed to identify noninvasive tumors. By definition, all of these tumors were encapsulated, partially encapsulated, or well circumscribed and lacked any indication of infiltrative growth, capsular penetration, or lymphovascular invasion.
RESULTS: Our cohort of 655 FNAs with subsequent resection specimens included 53 (8.1%) nondiagnostic (ND), 167 (25.5%) benign, 97 (14.8%) atypia/follicular lesion of undetermined significance (AUS/FLUS), 88 (13.4%) suspicious for follicular neoplasm (SFN), 94 (14.4%) suspicious for malignancy (SUS), and 156 (23.8%) malignant cases (POS). Surgical resections demonstrated benign findings in 309 (47.2%) and malignant tumors in 346 (52.8%), including 85 NFVPTCs accounting for 24.6% of malignancies. Our rates of malignancy for ND, benign, AUS/FLUS, SFN, SUS, and POS were 18.9%, 13.2%, 39.2%, 45.5%, 87.2%, and 98.7%, respectively. If NFVPTC were no longer termed carcinoma, these rates would drop to 17.0% (10% decrease), 5.4% (59% decrease), 21.6% (45% decrease), 37.5% (18% decrease), 45.7% (48% decrease), and 93.6% (5% decrease), respectively.
CONCLUSION: Our findings demonstrate that if terminology were changed and NFVPTCs were not considered carcinomas, the rates of malignancy for FNA diagnostic categories would be substantially decreased, with the most clinically significant decrease seen in the SUS category, which demonstrated a relative decrease of nearly 50%.

Entities:  

Mesh:

Year:  2015        PMID: 26114752     DOI: 10.1089/thy.2014.0612

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  37 in total

1.  European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics.

Authors:  Ralf Paschke; Silvia Cantara; Anna Crescenzi; Barbara Jarzab; Thomas J Musholt; Manuel Sobrinho Simoes
Journal:  Eur Thyroid J       Date:  2017-05-19

Review 2.  Molecular profiling of thyroid nodule fine-needle aspiration cytology.

Authors:  Markus Eszlinger; Lorraine Lau; Sana Ghaznavi; Christopher Symonds; Shamir P Chandarana; Moosa Khalil; Ralf Paschke
Journal:  Nat Rev Endocrinol       Date:  2017-03-31       Impact factor: 43.330

3.  Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on fine-needle aspiration diagnoses of thyroid nodules.

Authors:  Li Chen; Lina Liu; Parsa Hodjat; Bing Leng
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-23

4.  The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.

Authors:  Kristine S Wong; Kyle C Strickland; Trevor E Angell; Matthew A Nehs; Erik K Alexander; Edmund S Cibas; Jeffrey F Krane; Brooke E Howitt; Justine A Barletta
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

Review 5.  Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists.

Authors:  Raja R Seethala; Zubair W Baloch; Justine A Barletta; Elham Khanafshar; Ozgur Mete; Peter M Sadow; Virginia A LiVolsi; Yuri E Nikiforov; Giovanni Tallini; Lester Dr Thompson
Journal:  Mod Pathol       Date:  2017-10-20       Impact factor: 7.842

6.  Preoperative Diagnostic Categories of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Thyroid Core Needle Biopsy and Its Impact on Risk of Malignancy.

Authors:  Hee Young Na; Ji Won Woo; Jae Hoon Moon; June Young Choi; Woo-Jin Jeong; Yeo Koon Kim; Ji-Young Choe; So Yeon Park
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

7.  Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.

Authors:  Pablo Valderrabano; Laila Khazai; Zachary J Thompson; Kristen J Otto; Julie E Hallanger-Johnson; Christine H Chung; Barbara A Centeno; Bryan McIver
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-09-01       Impact factor: 6.223

8.  Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.

Authors:  Pablo Valderrabano; Laila Khazai; Marino E Leon; Zachary J Thompson; Zhenjun Ma; Christine H Chung; Julie E Hallanger-Johnson; Kristen J Otto; Kara D Rogers; Barbara A Centeno; Bryan McIver
Journal:  Endocr Relat Cancer       Date:  2017-01-19       Impact factor: 5.678

9.  Reclassification as NIFTP: a Retrospective Review in a Single Institution with an Emphasis on Workload.

Authors:  Kevin O'Hare; E O'Regan; A Khattak; M L Healy; M Toner
Journal:  Endocr Pathol       Date:  2018-09       Impact factor: 3.943

Review 10.  How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules.

Authors:  Kennichi Kakudo
Journal:  Gland Surg       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.